Can jaw-joint cartilage damage be treated without open surgery?

For most patients with jaw-joint cartilage damage, the instinctive worry is surgery — and in the TMJ, that concern is well founded. The joint sits immediately in front of the ear, in close proximity to the facial nerve, and at a depth that makes open or arthroscopic access considerably more technically demanding than equivalent procedures in the knee, hip, or ankle. The anatomical stakes are meaningfully higher, which makes a non-surgical route more than a matter of convenience.

ChondroFiller injection offers that route. The procedure is delivered as an ultrasound-guided outpatient treatment under local anaesthesia or mild sedation — no operating theatre, no general anaesthetic, and no requirement to surgically expose the joint. A small-bore cannula places the injectable collagen scaffold directly into the joint space, where it gels within minutes on contact with synovial fluid and adheres to the worn condylar surface.

This matters because the standard repertoire of TMJ care — splints, physiotherapy, corticosteroid injections, and hyaluronic acid viscosupplementation — manages pain and friction effectively for many patients, but none of these measures address the underlying cartilage loss. When those measures plateau and structural degeneration continues, a different intervention is needed. ChondroFiller injection is positioned at that point: an additive scaffold that coats and fills worn articular surfaces without the debridement of healthy tissue that surgical cartilage repair techniques require.

Why the jaw joint struggles to repair cartilage on its own

The TMJ houses two distinct cartilage structures — a fibrocartilage disc wedged between the temporal bone and mandibular condyle, and a fibrocartilage-lined layer covering the condylar surface beneath it. Both share a critical limitation: they are avascular, aneuric, and alymphatic. No blood vessels cross the tissue, so when wear or injury occurs, there is no vascular surge to deliver oxygen, inflammatory mediators, or the progenitor cells that trigger repair elsewhere in the body. Damage accumulates quietly, without the acute swelling or early warning signals that more vascularised tissues produce.

The cellular picture is equally discouraging. Single-cell transcriptomic analysis published in Nature Communications in 2023 mapped the behaviour of resident progenitor cells within the TMJ disc after injury. Rather than committing to cartilage-forming pathways, these cells converted into non-chondrogenic fibroblasts — essentially scar-forming cells that cannot rebuild articular tissue. The repair machinery is present but misdirected; the joint cannot reliably call on its own progenitors to restore what has been lost.

TMJ disorders affect an estimated 10–40% of the population, disproportionately younger women, often beginning years or even decades before joint replacement becomes a realistic consideration. That gap — between the onset of structural damage and the threshold for reconstruction — is precisely where an injectable scaffold approach has the strongest biological rationale.

How ChondroFiller injection works in the jaw joint

Injected as a liquid, ChondroFiller undergoes an immediate chemical transition once it contacts synovial fluid inside the joint. Within approximately 3–5 minutes, the acellular collagen scaffold gels in situ — forming a stable, viscoelastic 3D matrix that adheres to the worn condylar surface without any requirement to first evacuate or dry the joint space. This fluid-compatible gelation is particularly relevant in the TMJ, where earlier scaffold formulations faced a practical constraint: they needed a dry environment that the naturally fluid joint could not easily provide.

The resulting matrix is not inert. ChondroFiller is composed of highly purified murine-derived Type I collagen — a CE-marked Class III medical device — but contains no donor cells. Instead, the scaffold's architecture is chemotactic: it actively draws the patient's own progenitor cells from surrounding tissue into its three-dimensional structure. Those cells migrate into the collagen framework and begin differentiating along cartilage-forming pathways, a process known as matrix-induced chondrogenesis. As maturing repair tissue gradually fills the scaffold, the collagen degrades. The framework is temporary; the biology that replaces it is the patient's own.

Under ultrasound guidance, the injectable collagen is directed precisely to the inferior joint space — the compartment between the condyle and the fibrocartilage disc where condylar surface wear tends to concentrate — allowing targeted placement without open joint exposure.

What this process initiates, over weeks and months, is the progressive assembly of new cartilaginous tissue within the scaffold structure: a structural repair response rather than a transient adjustment to lubrication or inflammation.

What the evidence shows — and where the gaps are

The evidence sits at different levels of maturity depending on which joint is under consideration.

ChondroFiller's most robust clinical data come from the knee, where published series record IKDC scores improving by approximately 30 points over one year — a clinically meaningful gain on a validated patient-reported outcome measure. Structural imaging from wrist applications adds a further dimension, with reported reductions in bone marrow oedema and joint-space widening, suggesting the response may extend beyond symptom relief to measurable tissue-level change.

For the TMJ specifically, the evidence picture shifts markedly. No peer-reviewed randomised controlled trial or controlled outcome study evaluating ChondroFiller injection in the human jaw joint has been published as of mid-2026. Clinical benefit in this setting is extrapolated from CE-approved indications in other joints — a transparent and important limitation that prospective patients and referring clinicians should weigh clearly.

What does exist is mechanistically supportive preclinical work, conducted independently of ChondroFiller. In a mouse condylar defect model, mesenchymal stem cells combined with a hydrogel-biosilica composite restored intact articular surfaces and promoted chondrocyte maturation at four and eight weeks. A separate rat TMJ osteoarthritis study found that vesicles derived from dental pulp stem cells repaired subchondral bone damage and measurably reduced joint pain. These findings support the broad principle that injectable biological materials can reach the jaw joint and produce tissue-level responses — though they do not constitute clinical evidence for ChondroFiller specifically.

Two biological caveats deserve plain acknowledgement. The TMJ's articular surface is fibrocartilage rather than the hyaline cartilage of the knee; the quality of repair tissue stimulated may therefore differ from what knee data predict. Additionally, accurate ultrasound-guided access to the inferior TMJ joint space demands considerable specialist skill — technique sensitivity here is clinically meaningful, and outcomes are likely to vary with operator experience.

Who is likely to be suitable for ChondroFiller injection in the jaw

The patients most likely to benefit share a recognisable profile: a focal condylar cartilage lesion rather than diffuse, end-stage joint degeneration; a treatment history that has reached a structural plateau without resolving the underlying damage; and a joint that is compromised enough to warrant intervention but intact enough to mount a repair response.

Focal versus diffuse — the decisive distinction

A discrete, measurable area of condylar cartilage loss — the kind visible and quantifiable on MRI or CT arthrography — is the type of damage an injectable collagen scaffold can meaningfully address. The matrix can occupy that contained zone, coat the worn surface, and provide a chemotactic framework for the patient's own progenitor cells to migrate into and rebuild. Diffuse TMJ osteoarthritis, with widespread joint-space narrowing and subchondral remodelling across multiple compartments, falls outside this scope; that situation points toward joint preservation strategies or, in end-stage cases, a prosthetic replacement conversation.

Who typically presents

Condylar wear can develop in relatively young adults — often women in their thirties or forties — well before total joint replacement becomes appropriate. TMJ disorders affect an estimated 10–40% of the population, and this younger cohort with symptomatic structural damage frequently arrives having exhausted standard-care options without achieving structural improvement. ChondroFiller injection is designed specifically for patients at that point, where the clinical goal is to stabilise and regenerate rather than replace.

What an assessment determines

Even within the likely-suitable group, eligibility is not a matter of self-assessment. A clinical evaluation — combining examination with MRI or CT arthrography — will establish defect size and location, quantify remaining joint-space, and confirm whether degeneration has progressed beyond the point where scaffold injection is likely to be beneficial. Those findings are what determine whether ChondroFiller injection is the right next step.

Getting assessed at the London Cartilage Clinic

Liquid Cartilage™ (ChondroFiller injection) is available in the UK at the London Cartilage Clinic on Harley Street, the certified UK delivery centre for the treatment. Professor Paul Y. F. Lee leads ChondroFiller injection delivery at the clinic; in a joint as anatomically confined as the TMJ, precise image-guided placement is not incidental to the outcome — the same product delivers meaningfully different results depending on technique and the clinician administering it.

An initial assessment brings together recent imaging, defect characterisation, and a full review of previous treatment history. That clinical picture determines whether ChondroFiller injection is appropriate for the individual — and, if so, what a realistic treatment plan looks like.

Patients based in London or the commuter belt who have reached a structural plateau with standard TMJ care can book an assessment at londoncartilage.com.

1. [1] Mesenchymal Stem Cells for Cartilage Regeneration of TMJ Osteoarthritis. (2017). https://doi.org/10.1155/2017/5979741 https://doi.org/10.1155/2017/5979741
2. [2] Are Stem Cells Useful in the Regeneration and Repair of Cartilage Defects in the TMJ Condyle? An In Vivo Study. (2021). https://doi.org/10.26420/JDENTORALDISORD.2021.1159 https://doi.org/10.26420/JDENTORALDISORD.2021.1159
3. [3] Dental Pulp Stem Cell-Derived Intracellular Vesicles Promote Cartilage Regeneration and Alleviate Pain in Temporomandibular Joint Osteoarthritis. (2025). https://doi.org/10.1016/j.identj.2025.103974 https://doi.org/10.1016/j.identj.2025.103974
4. [4] A single-cell transcriptional atlas reveals resident progenitor cell niche functions in TMJ disc development and injury. (2023). https://doi.org/10.1038/s41467-023-36406-2 https://doi.org/10.1038/s41467-023-36406-2